• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [21642 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Luspatercept (transfusion-dependent beta-thalassaemia) – Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tixagevimab/cilgavimab (COVID-19) – Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Zanubrutinib (chronic lymphocytic leukaemia) – Addendum to Commission A22-130]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Risankizumab (Crohn disease) – Addendum to Commission A22-133]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Latanoprost/netarsudil (primary open-angle glaucoma and ocular hypertension) – Addendum to Commission A22-129]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Upadacitinib (Crohn disease) - Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cemiplimab (NSCLC, combination with platin-based chemotherapy) - Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cemiplimab (cervical cancer) – Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Lasmiditan (migraine) – Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Deucravacitinib (plaque psoriasis) – Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Routine practice data collection for brexucabtagene autoleucel: Review of the study protocol (Version 2.0) and statistical analysis plan (Version 2.0) – Third Addendum to Commission A21-130]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Olaparib (ovarian cancer) – Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Durvalumab (NSCLC) – Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tremelimumab (NSCLC) – Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dulaglutide (type 2 diabetes in children and adolescents) – Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Durvalumab (malignant biliary cystic tumour [BCT]) – Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dupilumab (atopic dermatitis, 6 months to 5 years) – Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dupilumab (prurigo nodularis) – Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Dupilumab (eosinophilic oesophagitis) – Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Darolutamide (prostate cancer) – Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Luspatercept (beta-thalassaemia) – Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Esketamine (treatment-resistant major depressive disorder) – Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Concept for routine practice data collection for brexucabtagene autoleucel acc. to the Law for More Safety in the Supply of Medicines (GSAV)]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [State of practice: use of healthcare services by people with confirmed SARS-CoV-2 infection and those with no documented evidence of infection]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: pediatric cancer predisposition using next-generation sequencing panels]
2023     Agency for Healthcare Research and Quality (AHRQ) Use of telehealth during the COVID-19 era
2023     Agency for Healthcare Research and Quality (AHRQ) Radiation therapy for metastatic bone disease: effectiveness and harms
2023     Agency for Healthcare Research and Quality (AHRQ) Postpartum care up to 1 year after pregnancy: a systematic review and meta-analysis
2023     Agency for Healthcare Research and Quality (AHRQ) Pharmacologic and nonpharmacologic treatments for posttraumatic stress disorder: an update of the PTSD repository evidence base
2023     Agency for Healthcare Research and Quality (AHRQ) Partial breast irradiation for breast cancer
2023     Agency for Healthcare Research and Quality (AHRQ) Nutrition as prevention for improved cancer health outcomes
2023     Agency for Healthcare Research and Quality (AHRQ) Nonemergent percutaneous coronary intervention versus optimal medical treatment for stable ischemic heart disease: a rapid response literature review
2023     Agency for Healthcare Research and Quality (AHRQ) Measuring healthcare organization characteristics in cancer care delivery research
2023     Agency for Healthcare Research and Quality (AHRQ) Management of postpartum hypertensive disorders of pregnancy
2023     Agency for Healthcare Research and Quality (AHRQ) Living systematic review on cannabis and other plant-based treatments for chronic pain
2023     Agency for Healthcare Research and Quality (AHRQ) Efficacy of dental services for reducing adverse events in those undergoing insertion of implantable cardiovascular devices
2023     Agency for Healthcare Research and Quality (AHRQ) Efficacy of dental services for reducing adverse events in those receiving chemotherapy for cancer
2023     Austrian Institute for Health Technology Assessment (AIHTA) Robot-assisted surgery in thoracic and visceral indications – Update 2023
2023     Norwegian Institute of Public Health (NIPH) [Brace compression for treatment of pectus carinatum: a rapid health technology assessment]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [Invasive electroencephalography for drug-resistant epilepsy]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [Transbronchial biopsy guided by endobronchial ultrasound (EBUS) in pathologies accesible by transbronchial puncture that required anatomopathological diagnosis]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [Dielectric radiofrequency for the treatment of primary hyperhidrosis and bromhidrosis]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [Triple-phase computed tomography in patients with liver lesion]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [Polymeric diet rich in TGF-β for inflammatory bowel disease in pediatric patients]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [Combination diagnostic tests offered as part of preventive health checks exams in overall population]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [Sapropterin in patients with phenylketonuria]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [Holmium laser in non-prostate endourologic conditions]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [Lipogems® System for autologous adipose tissue-derived mesenchymal stem cells transfer in orthopedic conditions]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [Mobile cardiopulmonary exercise test in athletes or cardiopulmonary rehabilitation]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [Lecanemab in Alzheimer’s Disease]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [Angioplasty and stenting in patients with carotid artery stenosis]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [Non-invasive monitoring of intracranial compliance and intracranial pressure in central nervous system lesions]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: virtual care in psychiatry]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: virtual care in respirology]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: virtual care in pediatrics]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: virtual care in neurology]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: virtual care in internal medicine]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: virtual care in hematology/oncology]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: virtual care in general surgery]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: optical genome mapping - diagnosis and prognostic stratification of hematological malignancies]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: virtual genes panels of pediatric cancers by NGS of somatic exome and transcriptome - evaluation report of an analysis developed by the RQDM]
2023     Health Information and Quality Authority (HIQA) Expansion of the childhood immunisation schedule to include varicella (chickenpox) vaccination: health technology assessment
2023     Health Information and Quality Authority (HIQA) Interventions to improve long COVID symptoms: a systematic review
2023     Health Information and Quality Authority (HIQA) A slot-scanning, biplanar, digital X-ray imaging system for the evaluation and monitoring of orthopaedic conditions: evidence synthesis to support a generic justification decision
2023     Health Information and Quality Authority (HIQA) Lutetium oxodotreotide for the treatment of metastatic or inoperable gastroenteropancreatic neuroendocrine tumours (GEP-NETs): evidence synthesis to support a generic justification decision
2023     Adelaide Health Technology Assessment (AHTA) Abdominal MRI for rare genetic conditions associated with increased risk of renal tumours
2023     Adelaide Health Technology Assessment (AHTA) Review of different minimally invasive therapeutic approaches for the management of patients with benign prostatic hyperplasia
2023     Adelaide Health Technology Assessment (AHTA) Whole genome sequencing for the diagnosis of mitochondrial disease
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Newsletter: An overview of precision medicine initiatives here and elsewhere]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Newsletter: overview of interventions addressed by some evaluation agencies outside Quebec - an exploration of the diversity of potential evaluation topics]
2023     Penn Medicine Center for Evidence-based Practice (CEP) Nurse-driven protocols for antibiotic initiation in febrile neutropenia
2023     Austrian Institute for Health Technology Assessment (AIHTA) Electrical auricular vagus nerve stimulation for pain
2023     Austrian Institute for Health Technology Assessment (AIHTA) Bleomycin electrosclerotherapy for vascular anomalies
2023     Austrian Institute for Health Technology Assessment (AIHTA) Transcranial magnetic resonance-guided high-intensity focused ultrasound treatment in patients with drug-resistant essential tremor
2023     Austrian Institute for Health Technology Assessment (AIHTA) Percutaneous aspiration thrombectomy for pulmonary embolism
2023     Austrian Institute for Health Technology Assessment (AIHTA) 177Lu-PSMA radioligand therapy in patients with metastatic castration-resistant prostate cancer: Update 2023 - systematic review
2023     Austrian Institute for Health Technology Assessment (AIHTA) Allogeneic mesenchymal stem cells for Crohn's disease-associated complex perianal fistulas. Update 2023
2023     Austrian Institute for Health Technology Assessment (AIHTA) Percutaneous mitral valve repair with a clip device in patients with mitral regurgitation. Update 2023
2023     Austrian Institute for Health Technology Assessment (AIHTA) [Radiofrequency denervation for chronic lumbar or cervical spine pain]
2023     NIHR Health Services and Delivery Research programme The effects of computerised decision support systems on nursing and allied health professional performance and patient outcomes: a systematic review and user contextualisation
2023     NIHR Health Services and Delivery Research programme Youth violence intervention programme for vulnerable young people attending emergency departments in London: a rapid evaluation
2023     NIHR Health Services and Delivery Research programme New and emerging technology for adult social care - the example of home sensors with artificial intelligence (AI) technology
2023     NIHR Health Services and Delivery Research programme Early evaluation of the Children and Young People's Mental Health Trailblazer programme: a rapid mixed-methods study
2023     NIHR Health Services and Delivery Research programme Towards achieving interorganisational collaboration between health-care providers: a realist evidence synthesis
2023     NIHR Health Services and Delivery Research programme Thinking ahead about medical treatments in advanced illness: a qualitative study of barriers and enablers in end-of-life care planning with patients and families from ethnically diverse backgrounds
2023     NIHR Health Services and Delivery Research programme A multimethod study of NHS 111 online
2023     NIHR Health Services and Delivery Research programme Factors which facilitate or impede patient engagement with pulmonary and cardiac rehabilitation: a rapid evaluation mapping review
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: rapid assessment zones in emergency departments - organizational characteristics and their impact]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: measurement and monitoring of total serum bilirubin in a newborn with signs suggestive of neonatal jaundice]
2023     NIHR Health Technology Assessment programme Antibiotics for lower respiratory tract infection in children presenting in primary care: ARTIC-PC RCT
2023     NIHR Health Technology Assessment programme Bleeding risk in patients prescribed dual antiplatelet therapy and triple therapy after coronary interventions: the ADAPTT retrospective population-based cohort studies
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [State of practice: developing portraits to support the ongoing adaptation of youth services by local service networks]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: relevant practices for promoting hearing health in long-term residential care settings]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: Prolastin-C Liquid – congenital alpha1-antitrypsin deficiency]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: Glassia – congenital alpha1- antitrypsin deficiency]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: Zemaira - congenital alpha1- antitrypsin deficiency]
2023     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: acute exacerbation of chronic obstructive pulmonary disease -diagnostic approach, optimal use of treatments, and follow-up]
2023     Scottish Health Technologies Group (SHTG) Technology enabled theatre scheduling tools
2023     The Federal Joint Committee (G-BA) Pharmaceutical Directive/Annex XII: Brexucabtagen Autoleucel (new therapeutic indication: relapsed or refractory B-cell precursor acute lymphoblastic leukaemia, 26 years of age and above)
2023     Health Sciences Institute in Aragon (IACS) [Effectiveness, safety and efficiency of subconjunctival drainage devices using an ab-internal approach for primary open-angle glaucoma surgery]